Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer

doi:10.4240/wjgs.v17.i6.106361

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (240)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-4)

Sum=186

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=45

Jun 27, 2025 (publication date) through Jun 6, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Jun 27, 2025; 17(6): 106361
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106361

Open in New Tab Full Size Figure Download Figure

Figure 1 Flow diagram of the patient selection process. ICI: Immune checkpoint inhibitor.

Open in New Tab Full Size Figure Download Figure

Figure 2 Survival curves. A: Disease free survival for group immune checkpoint inhibitor (ICI) and group non-ICI (P = 0.043); B: Overall survival for group ICI and group non-ICI (P = 0.816). DFS: Disease-free survival; OS: Overall survival; ICI: Immune checkpoint inhibitor.

Open in New Tab Full Size Figure Download Figure

Figure 3 Immunohistochemistry. A and B: Expression of combined positive score in group immune checkpoint inhibitor (ICI); C: Expression of mismatch repair in group ICI; D: Expression of Epstein-Barr virus in group ICI; E: Expression of human epidermal growth factor receptor 2 in group ICI. CPS: Combined positive score; TRG: Tumor regression grading; pMMR: DNA proficient mismatch repair; dMMR: DNA deficient mismatch repair; EBV: Epstein-Barr virus; HER-2: Human epidermal growth factor receptor 2.

Citation: Chen QX, Zhang YB, Zeng WM, Cai YC, Lv CB, Lian MQ, Huang RJ, Lian MJ, Lian WL, Xu QH, Sun YQ, Cai LS. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. World J Gastrointest Surg 2025; 17(6): 106361
URL: https://www.wjgnet.com/1948-9366/full/v17/i6/106361.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i6.106361